Group 1 - Boston Scientific Corporation will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, in San Francisco, with a 40-minute Q&A session featuring key executives [1] - The company will host a conference call on February 4, 2026, at 8:00 a.m. ET to discuss financial results for Q4 and the full year ended December 31, 2025 [2] - A news release announcing the financial results will be issued prior to the conference call on February 4 [2] Group 2 - Boston Scientific is a global medical technology leader with over 45 years of experience, focusing on innovative medical technologies that improve patient health [4] - The company's portfolio includes high-performance solutions for diagnosing and treating complex diseases across various medical fields, including cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions [4]

Core Viewpoint - Masimo Corp. achieved a significant legal victory against Apple Inc. with a $634 million judgment, yet its underlying fundamentals indicate potential weaknesses in operational efficiency and financial health [1][6]. Fundamentals Under Pressure - Masimo's quality score has decreased to 10.43, placing it in the bottom tier of stocks for operational efficiency, indicating underperformance compared to nearly 90% of the market [2][3]. - The company's core operational metrics and historical profitability remain weak relative to industry competitors, despite the cash influx from the lawsuit [3]. Technical Indicators - The stock's momentum score is low at 8.77, reflecting weak relative strength and price movement patterns compared to other stocks [4]. - Masimo's stock is experiencing a downward trend across short, medium, and long timeframes, indicating persistent selling pressure over the past year [5]. Legal Victory - A federal jury in California ruled that Apple infringed on Masimo's blood-oxygen sensor patents, resulting in a $634 million award to Masimo, which the company views as a significant win for its innovation efforts [6]. Stock Performance - In 2025, Masimo's shares dropped by 22.85%, underperforming against the Nasdaq Composite index, which gained 20.54% during the same period [7]. - Over the last six months, the stock fell by 24.09%, closing the last trading day of 2025 at $130.06, with no change in pre-market trading [7].

Company Overview - NovoCure (NVCR) is a medtech company that specializes in developing, manufacturing, and selling proprietary Tumor Treating Fields (TTFields) devices aimed at treating solid tumor cancers [1] Product Information - The company currently markets two products, including Optune Gio, which is specifically designed for the treatment of certain types of cancers [1] Investment Perspective - The Stock Research Platform (SRP) is actively screening the market for companies like NovoCure that possess a strong balance sheet, sustainable growth pathways, and valuations that present significant upside potential with limited downside risk [1]

Company Overview - NovoCure (NVCR) is a medtech company that specializes in developing, manufacturing, and selling proprietary Tumor Treating Fields (TTFields) devices aimed at treating solid tumor cancers [1] - The company currently markets two products, including Optune Gio, which is specifically designed for the treatment of certain types of cancers [1] Investment Insights - The Stock Research Platform (SRP) is actively screening the market for companies like NovoCure that possess a strong balance sheet and a sustainable growth pathway, indicating potential for significant upside with limited downside risk [1]

Group 1 - Haemonetics Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 7:30 am Pacific Time [1] - The presentation will be accessible via a live audio webcast and will be available for replay for 30 days after the event [1] - Haemonetics is a global medical technology company focused on improving healthcare quality, effectiveness, and efficiency [2] Group 2 - The company offers innovative solutions including hospital technologies, plasma collection technologies, and products for blood centers [2] - Haemonetics aims to advance standards of care and enhance patient outcomes through its technologies [2]

Core Viewpoint - Intelligent Bio Solutions Inc. is experiencing a significant increase in stock price and trading volume due to a new strategic manufacturing partnership with Syrma Johari MedTech Ltd. aimed at enhancing production capabilities and improving margins [2][6]. Group 1: Partnership and Production - Intelligent Bio has announced a strategic manufacturing partnership with Syrma Johari MedTech Ltd. to support and scale the production of its Intelligent Fingerprinting Drug Screening Reader [2]. - The partnership is expected to yield substantial operational and financial benefits, including annual production cost savings of over 40% and an approximate 20 percentage point improvement in gross margin compared to previous arrangements [3][4]. - Syrma Johari's manufacturing capacity is about four times that of Intelligent Bio's current capacity, enabling the company to meet anticipated demand as it scales its commercial operations [4]. Group 2: Supply Chain and Market Strategy - The collaboration enhances Intelligent Bio's global manufacturing strategy by reducing reliance on a single supplier and increasing resilience in its supply chain [4]. - The partnership broadens manufacturing capacity, ensures continuity, and creates flexibility in preparation for future demand, including a planned U.S. market entry in 2026 [5]. - Syrma Johari operates 14 manufacturing locations and four design and innovation centers across India, Europe, and the United States, and is set to open a new medical-grade plastics manufacturing facility in India in January 2026 [5]. Group 3: Stock Performance - Intelligent Bio Solutions shares rose by 114.63% to $8.80 at the time of publication, reflecting strong market interest and confidence in the company's strategic moves [6].

Core Insights - Sentiment plays a crucial role in the performance of small-cap med-tech stocks, particularly during their early commercialization phases [1] - Significant coverage decisions for Sight Sciences' TearCare dry eye treatment have positively influenced the company's outlook since the last update [1] Company Overview - Sight Sciences (SGHT) has made notable progress in its commercialization efforts, particularly with its TearCare product [1]

Core Viewpoint - Ventripoint Diagnostics Ltd. is conducting a non-brokered private placement to raise up to $500,000 through the issuance of 5,000,000 units at a price of $0.10 per unit, subject to regulatory approval [1][5]. Group 1: Offering Details - Each unit consists of one common share and one common share purchase warrant, with the warrants allowing the purchase of additional shares at $0.13 for 24 months [2]. - The corporation may pay a cash finder's fee and issue finder's warrants up to 8% of the gross proceeds, with each finder's warrant also exercisable at $0.13 for 24 months [3]. - The proceeds from the offering will be allocated to operational costs, sales and marketing, hiring key personnel, and general working capital [4]. Group 2: Regulatory and Compliance Information - All securities issued will be subject to a hold period of four months plus one day from the closing date of the offering [5]. - The securities will not be registered under the U.S. Securities Act of 1933 and cannot be offered or sold in the United States without proper registration or exemption [6]. Group 3: Company Overview - Ventripoint has established itself as a leader in applying AI to echocardiography, with its VMS+ products providing accurate cardiac measurements comparable to MRI [8]. - The technology is a cost-effective alternative that enhances cardiologists' confidence in patient management and is compatible with all ultrasound systems from various vendors, supported by regulatory approvals in the U.S., Europe, and Canada [8].

Core Insights - Zacks Premium offers various tools for investors, including daily updates on stock rankings and industry performance, aimed at long-term investment success [1][2] Focus List Overview - The Zacks Focus List is a curated portfolio of 50 stocks designed for long-term investors, expected to outperform the market over the next 12 months [3] - Each stock in the Focus List is supported by a full Zacks Analyst Report, detailing the rationale behind its selection [4] Performance Metrics - In 2020, the Focus List achieved an annualized gain of 13.85%, outperforming the S&P 500's return of 9.38% - Cumulatively, from February 1, 1996, to March 31, 2021, the Focus List returned 2,519.23%, while the S&P 500 returned 854.95% [5] Methodology - The selection process for the Focus List relies on earnings estimate revisions, which are influenced by brokerage analysts who assess various factors affecting future earnings [6] - Positive changes in earnings estimates are likely to lead to further upward revisions, indicating potential for stock price increases [7] Zacks Rank System - The Zacks Rank is a proprietary model that uses changes in quarterly earnings expectations to guide investors in building a successful portfolio [8] - Stocks are classified into five groups based on four main factors: Agreement, Magnitude, Upside, and Surprise, with the Focus List primarily featuring 1 (Strong Buy) and 2 (Buy) ranked stocks [9] Stock Price Dynamics - Stocks with rising earnings estimates tend to experience price momentum, making Focus List stocks attractive for investment [10][11] Company Spotlight: GE HealthCare Technologies - GE HealthCare Technologies operates in four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, focusing on integrated solutions in medtech [12] - Since its addition to the Focus List on January 4, 2023, GEHC shares have increased by 37.46%, from $60.49 to $83.15, and currently holds a 3 (Hold) rating on the Zacks Rank [13]

MESA, ARIZONA / ACCESS Newswire / December 30, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) today announced that it has updated its corporate website, www.medicalcaretechnologies.com, to feature the Company's newly launched expedited approach to reaching international markets with its artificial intelligence ("AI") powered mobile applications. The website update highlights the Company's expansion into its new category of AI Lifestyle & Wellness Applications, which leverage the Company's patent-pend ...